Incidence and Risk Factors of Post Thrombolysis Intracranial Hemorrhage in Acute Ischemic Stroke, Bueng Kan Hospital

Authors

  • Warut Chompoochan Department of Medicine, Bueng Kan Hospital, Bueng Kan Province

Keywords:

risk, thrombolytic drug, intracranial hemorrhage, acute ischemic stroke

Abstract

Introduction:  Ischemic stroke is a primary cause of mortality and disability in Thailand. Thrombolytic drug (rt-PA) can result in effective treatment. However rt-PA has been associated with cerebral hemorrhages which can worsen a patient’s symptoms and can lead to death. This study aimed to investigate the factors for cerebral hemorrhages after attaining rt-PA. The results from this study should help to prevent and lower mortality rates caused by ischemic stroke.

          Methodology: A retrospective study, the information of patients who diagnosis acute ischemic strokes. Patient data is obtained from the admission medical record and collected from Bueng Kan Hospital between 2014 to 2020. The collected data involved the following characteristic information, clinical information and clinical outcome after thrombolysis was analyzed and investigated risk factors for ICH by multivariable method         

Results: There were 176 acute ischemic stroke patients who had received rt-PA. Of this group of patients, 21% had experienced cerebral hemorrhage (9.1 % for symptomatic intracranial hemorrhage, sICH and 11.9% for asymptomatic intracranial hemorrhage, aICH). The following factors that were found to have associated to cerebral hemorrhages with NIHSS scores in the ranges of 16-20, advance age, obesity, hypertension, cardioembolism. Multivariable analysis was observed that the primary causes of cerebral hemorrhage after rt-PA had been hypertension and cardioembolism (OR 3.61, 95%CI and OR 4.72, 95%CI, respectively). 

Conclusion: At the NIHSS range of 16-20, advance age, obesity, hypertension, Atrial fibrillation, ischemic stroke cardioembolism all type represent potential factors that could cause cerebral hemorrhages after rt-PA.

   

Downloads

Download data is not yet available.

References

Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and Stroke statistics-2021 update: a report from American Heart Association. Circulation 2021;143(8):doi:10.1161/CIR.0000000000000950

Suwanwela NC. Stroke Epidemiology in Thailand. J stroke 2014;16(1):1-7.

Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M, et al. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012;79(4):306-13.

Switzer JA, Hess DC. Development of regional programs to speed treatment of stroke. Curr neurol Neurosci Rep 2008;8(1):35-42.

Meretoja A, Weil L, Ugalde M, Yassi N, Yan B, Hand P, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology 2013;81(12):1071-6.

บดีภัทร วรฐิติอนันต์, ชัชฎาพร โอศิริ. การพัฒนาการจัดการโรคหลอดเลือดสมองขาดเลือดเฉียบพลันผ่านช่องทางด่วน ณ ห้องฉุกเฉิน รพ.นครปฐม. วารสารแพทย์เขต 4-5 2560;36(4):251-63.

Ratanakorn D, Keandoungchun J. Cerebrovascular disease. In: Limpijankit T, Kiertiburanakul S, Sungkanuparph S, editors. Emergency in medicine. 2nd ed. Bangkok: Beyond enterprise Co.,Ltd; 2007.

Nijasri Chanranarong. Management of acute ischemic stroke. Bangkok: Chulalongkorn University Publisher; 2007.

Gajurel BP, Dhungana K, Parajuli P, Karn R, Rajbhandari R, Kafle D, et al. The National Institute of Health Stroke Scale Score and Outcome in Acute Ischemic Stroke. Journal of Institute of Medicine 2014;36:9-13.

National Institute of Neurological Disorder and Stroke rt-PA stroke study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581-7.

Yamaguchi T, Mori E, Minemutsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37(7):1860-5.

Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischemic stroke in the safe implementation of thrombolysis in stroke monitoring study (SITS-MOST): an observational study. Lancet 2007;369(9558):275-82.

Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al. Routine use of intravenous low dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 2009;40(11):3591-5.

Nakagawara J, Minemutsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: The Japan post-marketing alteplase registration study (J-MARS). Stroke 2010;41(9):1984-9.

Liu M, Pan Y, Zhou L, Wang Y. Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke. PLos One 2017;12(9):e0184646.

พิมพ์ไทย นามโพธิ์. การศึกษาความชุกของภาวะเลือดออกในสมองหลังการได้รับยาละลายลิ่มเลือด recombinant tissue-type plasminogen activator (rt-PA) ในผู้ป่วยโรคหลอดเลือดสมองตีบ

หรืออุดตันเฉียบพลัน ที่ห้องฉุกเฉินโรงพยาบาลชัยภูมิ. วารสารสุขภาพและสิ่งแวดล้อมศึกษา 2564;6(1):59-65.

Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systemic review and meta-analysis of 55 studies. Stroke 2012;43(11):2904-9.

Dharmasaroja PA, Muengtaweepongsa S, Pattaraarchachai J, Dharmasaroja P. Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke. J Clin Neurosci 2012;19(6):799-803.

Warinthorn P, Kittisak S, Boonrerk S, Somsak T, Kannikar K, Verajit C, et al. Risk factor for intracerebral hemorrhage after treatment with recombinant tissue-type plasminogen activator for acute ischemic stroke. Asian Biomedicine 2015;9(3)397-400.

Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systemic review and meta-analysis of 55 studies. Stroke 2012;43(11):2904-9.

Dharmasaroja PA, Muengtaweepongsa S, Pattaraarchachai J, Dharmasaroja P. Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke. J Clin Neurosci 2012;19(6):799-803.

Warinthorn P, Kittisak S, Boonrerk S, Somsak T, Kannikar K, Verajit C, et al. Risk factor for intracerebral hemorrhage after treatment with recombinant tissue-type plasminogen activator for acute ischemic stroke. Asian Biomedicine 2015;9(3)397-400.

Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan YY. Part 11: adult stroke: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010;122(18 Suppl 3):S818-28.

ปาริชาติ ตุ้มทอง. ปัจจัยที่มีผลต่อการเกิดเลือดออกในสมองหลังการรักษาด้วยยาละลายลิ่มเลือดในผู้ป่วยโรคหลอดเลือดสมองตีบหรืออุดตันฉับพลัน [อินเทอร์เน็ต]. 2563 [เข้าถึงเมื่อ 15 ก.พ.2564]. เข้าถึงได้จาก: 203.157.71.172/academic.web/file2/2564.

สิโรตม์ ศรีมหาดไทย. ปัจจัยที่มีผลต่อการมีเลือดออกในสมองสำหรับผู้ป่วยหลอดเลือดสมองอุดตันที่ได้รับยา rtPA. วารสารแพทย์เขต 4-5 2563;39(4):604-15.

พัณน์ญรัศ พันธุ์เขียน. ปัจจัยที่มีผลต่อการเกิดเลือดออกในสมอง ตามหลังการให้รีคอมบิแนนท์ ทิชชู พลาสมิโนเจน แอคทีเวเตอร์ ทางหลอดเลือดดำ. วารสารแพทย์เขต 4-5 2558;34(2):120-30.

สุจริต สวนกูล, ธานินทร์ โลเกศกระวี. ปัจจัยที่มีผลต่อภาวะเลือดออกในสมองภายหลังการให้ยาละลายลิ่มเลือดทางหลอดเลือดดำในผู้ป่วยโรคหลอดเลือดสมองตีบหรืออุดตันเฉียบพลัน. ลำปางสาร 2559;37(2):67-77.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Eng J med 2008;359(13):1317-29.

Chonvipa Siriyutwattana, Suwat Srisuwannanukorn, Supharat Winitprichakul. Incidence and associated factors of intracranial hemorrhage after intravenous thrombolysis for acute ischemic stroke in Vajira hospital. Thai Journal of Neurology 2020;36(2):51-6.

Yaghi S, Willey JZ, Cucchiara B, Goldstein JN, Gonzales NR, Khatri P, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for health care professionals from the American Heart Association/American Stroke Association. Stroke 2017;48(12):e343-e61.

พิมพ์กานต์ หล่อวณิชย์, วสันต์ ลิ่มสุริยกานต์. ปัจจัยที่เกี่ยวข้องกับภาวะเลือดออกในสมองในผู้ป่วยโรคสมองขาดเลือดที่ได้รับ rtPA ในโรงพยาบาลพระนครศรีอยุธยา.TUH Journal online 2021;6(1):12-20.

Zhang X, Yu Y, Jaing L, Chen T, Sang Y, Wang Y, et al. The risk factors of early hemorrhage after emergency intravenous thrombolysis in patients with acute ischemic stroke. Ann Palliat Med 2021;10(5):5706-13.

Balami JS, Sutherland BA, Buchan AM. Complications associated with recombinant tissue plasminogen activator therapy for acute ischemic stroke. CNS Neurol Disord Drug Targets 2013;12(2):155-69.

Dong MX, Hu QC, Chen P, Pan JX, Wei YD, Liu YY, et al. Recombinant tissue plasminogen activator induces neurological side effects independent on thrombolysis in mechanical animal models of focal cerebral infarction: a systemic review and meta-analysis. PloS One 2016;11(7):e0158848.

Warut Chompoochan. Clinical features and treatment outcomes of severe strokes in Thailand: Real-world practice in hospitals across Thailand. Thai Journal of Neurology 2020; 36(1):31.

Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, et al. Marker of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice:the mu;ticenter rt-PA stroke Survey. Circulation 2002;105(14):1679-85.

Miller DJ, Simpson JR, Silver B. Safety of thrombolysis in acute ischemic stroke: a review of complication, risk factors, and newer technologies. Neurohospitalist 2011;1(3):138-47.

Strbian D, Meretoja A, Ahlhelm FJ, Pitkneimi J, Lyser P, Kaste M, et al. Predicting the outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology 2012;78(6):427-32.

Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neural 2012;71(5):634-41.

Published

2022-05-18

How to Cite

1.
Chompoochan W. Incidence and Risk Factors of Post Thrombolysis Intracranial Hemorrhage in Acute Ischemic Stroke, Bueng Kan Hospital. JPMAT [Internet]. 2022 May 18 [cited 2022 Sep. 26];12(1):82-99. Available from: https://he01.tci-thaijo.org/index.php/JPMAT/article/view/252306

Issue

Section

Research Article